scholarly journals GENDER FEATURES OF MORBIDITY IN CORRECTIONAL FACILITIES OF THE RUSSIAN FEDERATION

2017 ◽  
pp. 33-37
Author(s):  
E.A. Samarina ◽  
S.B. Ponomaryov ◽  
S.A. Sterlikov
Keyword(s):  
Russian Federation ◽  
Cerebrovascular Diseases ◽  
Mastoid Process ◽  
Chronic Obstructive ◽  
Peripheral Nervous System Diseases ◽  
Obstructive Pulmonary Disease ◽  
Ulcer Disease ◽  
The Russian Federation ◽  
Artery Disease ◽  
Gender Based

A comparison of the morbidity for different classes of diseases and groups of diseases for women and men who are in prisons of the Russian Federation. The morbidity of the disease by separate nosological units and groups of women in prison is higher than that of men by: neoplasms, thyrotoxicosis, obesity, diabetes mellitus, diseases of the blood and blood-forming organs, certain immune disorders, rheumatoid arthritis, non-infectious enteritis and colitis, bronchitis chronic and unadjusted, hypertension, asthma and asthmatic conditions, chronic disease of tonsils and adenoids, disease of the gallbladder and biliary tract, osteoporosis, pancreatic diseases, cerebrovascular diseases, rheumatic valvular disease, peripheral nervous system diseases, insulin-dependent diabetes, infectious and parasitic diseases, mental and behavioral disorders, arthrosis. Men were sick more often than women by ankylosing spondylitis, acute myocardial infarction, peptic ulcer disease, atherosclerosis of arteries, injuries, poisoning and certain other consequences of external reasons, reactive arthropathy, chronic rhinitis, pharyngitis, nasopharyngitis. There was no gender-based frequency eye diseases and adnexa, ear and mastoid process, pneumonia, chronic obstructive pulmonary disease, liver disease, kidney stones, coronary artery disease, acute rheumatic fever, epilepsy and status epilepticus.

Medical and economic analysis of the consequences of expanding the drug supply program for patients with chronic obstructive pulmonary disease in the Russian Federation

2019 ◽  
pp. 53-61
Author(s):  
Andrei Georgievich Maliavin ◽  
Alana Viktorovna Dzanaeva ◽  
Maria Vladimirovna Avxentyeva ◽  
Sergei Lvovich Babak
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Russian Federation ◽  
Chronic Obstructive ◽  
Outpatient Basis ◽  
Basic Drug ◽  
Obstructive Pulmonary Disease ◽  
Basic Therapy ◽  
The Russian Federation ◽  
The Cost ◽  
Drug Provision

Purpose of the study. Healthcare budget impact analysis in the Russian Federation of providing adult patients with chronic obstructive pulmonary disease (COPD) with basic therapy for outpatient treatment. Material and methods. The hypothesis of reducing costs for the treatment of exacerbations of COPD was tested while providing all patients with basic therapy on an outpatient basis. The model calculates the direct medical costs of drug provision and treatment of exacerbations in patients with COPD in the current situation and when all patients with COPD are covered with basic therapy as part of a program of preferential drug provision. The simulation period is 1 year. The analysis does not take into account social losses associated with disability, payment of disability certificates, reduced labor productivity and mortality. Results. The cost of providing all patients with COPD with the recommended basic drug therapy on an outpatient basis is substantially offset by a decrease in the cost of treating exacerbations: drug costs should increase by 14.1 billion rubles compared with the current situation, while the cost of providing medical care to patients with exacerbations is reduced by 9.7 billion rubles. As a result, the difference in direct medical costs, or the necessary additional investments, is 4.4 billion rubles. The price of drugs used for basic therapy has the greatest impact on the size of the required additional investments. Conclusion. Providing all patients with COPD with the recommended basic drug therapy on an outpatient basis, we can expect a decrease in the number of moderate exacerbations per year by 14.7% and severe exacerbations by 31.2%. Taking into account not only medical, but also socio-economic costs can not only offset additional investments, but also demonstrate significant savings. When implementing a pilot project of preferential drug provision for patients with COPD in a specific region of the Russian Federation, it is possible to reduce the cost of purchasing medicines when forming a municipal order.

scholarly journals MORTALITY FROM CIRCULATORY SYSTEM DISEASES IN THE KEMEROVO REGION AND THE RUSSIAN FEDERATION IN 2000–2016

2019 ◽  
Vol 8 (2) ◽  
pp. 6-11
Author(s):  
S. A. Makarov ◽  
S. A. Maksimov ◽  
E. B. Shapovalova ◽  
D. S. Stryapchev ◽  
G. V. Artamonova
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Russian Federation ◽  
Circulatory System ◽  
Mortality Rates ◽  
Cerebrovascular Diseases ◽  
Circulatory System Diseases ◽  
The Russian Federation ◽  
Artery Disease ◽  
Regional Mortality

Aim. To estimate the trends in mortality from circulatory system diseases, including coronary artery disease and cerebrovascular diseases, in the Kemerovo region in the period from 2000 to 2016 and compare it with the national trends.Methods. Data on national mortality rates, including those among adults of working age (men 16–59 years, women 16–54 years) from circulatory system diseases, coronary artery disease and cerebrovascular diseases in the period from 2000 to 2016 were obtained through the national statistical reports. A linear trend in the regional mortality rate to the national one has been reported.Results. Mortality rate from circulatory system diseases in the period from 2000 to 2016 tends to a decrease in the Kemerovo region and the Russian Federation. The comparative analysis of mortality rates in the Kemerovo region and the Russian Federation reported lower regional mortality rates in the general population. Despite lower mortality rates from coronary artery disease in the general population and working population, there are higher mortality rates from cerebrovascular diseases. Conclusion. The trend in mortality from circulatory system diseases in the Kemerovo region is comparable to that in the Russian Federation. Specific regional features related to the interaction of various factors, including regional healthcare system, have been determined. The trends in mortality from coronary artery disease and cerebrovascular diseases in the period from 2000 to 2016 have been presented.

scholarly journals An Emerging Syndemic of Smoking and Cardiopulmonary Diseases in People Living with HIV in Africa

2021 ◽  
Vol 18 (6) ◽  
pp. 3111
Author(s):  
Emmanuel Peprah ◽  
Mari Armstrong-Hough ◽  
Stephanie H. Cook ◽  
Barbara Mukasa ◽  
Jacquelyn Y. Taylor ◽  
...  
Keyword(s):  
Current Evidence ◽  
Chronic Obstructive ◽  
People Living With Hiv ◽  
African Countries ◽  
Obstructive Pulmonary Disease ◽  
Cardiopulmonary Disease ◽  
Current Trends ◽  
Significant Public Health ◽  
Artery Disease ◽  
Living With Hiv

Background: African countries have the highest number of people living with HIV (PWH). The continent is home to 12% of the global population, but accounts for 71% of PWH globally. Antiretroviral therapy has played an important role in the reduction of the morbidity and mortality rates for HIV, which necessitates increased surveillance of the threats from pernicious risks to which PWH who live longer remain exposed. This includes cardiopulmonary comorbidities, which pose significant public health and economic challenges. A significant contributor to the cardiopulmonary comorbidities is tobacco smoking. Indeed, globally, PWH have a 2–4-fold higher utilization of tobacco compared to the general population, leading to endothelial dysfunction and atherogenesis that result in cardiopulmonary diseases, such as chronic obstructive pulmonary disease and coronary artery disease. In the context of PWH, we discuss (1) the current trends in cigarette smoking and (2) the lack of geographically relevant data on the cardiopulmonary conditions associated with smoking; we then review (3) the current evidence on chronic inflammation induced by smoking and the potential pathways for cardiopulmonary disease and (4) the multifactorial nature of the syndemic of smoking, HIV, and cardiopulmonary diseases. This commentary calls for a major, multi-setting cohort study using a syndemics framework to assess cardiopulmonary disease outcomes among PWH who smoke. Conclusion: We call for a parallel program of implementation research to promote the adoption of evidence-based interventions, which could improve health outcomes for PWH with cardiopulmonary diseases and address the health inequities experienced by PWH in African countries.

Antithrombotic therapy in multimorbid patients with atrial fibrillation from standpoint of clinical recommendations of Ministry of Health of Russian Federation (2020). Effectiveness and safety of apixaban in patients with atrial fibrillation and concomitant diseases

2021 ◽  
Vol 1 (11) ◽  
pp. 12-19
Author(s):  
O. D. Ostroumova ◽  
V. N. Butorov ◽  
N. A. Arablinsky ◽  
R. R. Romanovsky ◽  
S. V. Batyukina
Keyword(s):  
Atrial Fibrillation ◽  
Russian Federation ◽  
Scientific Research ◽  
Chronic Obstructive ◽  
Efficacy And Safety ◽  
Ministry Of Health ◽  
Obstructive Pulmonary Disease ◽  
Risk Of Death ◽  
Post Hoc ◽  
Multimorbid Patients

Clinical practice and ongoing scientific research in recent years show the importance of the problem of multimorbidity in atrial fibrillation (AF). The prevalence of AF in the general population is 1–2%, while the frequency of its occurrence increases with age – from less than 0.5% at the age of 40–50 to 5–15% at the age of 80. Only 19.6% of patients with AF have no comorbidities, 69.3% of patients have 1 to 3 comorbidities, and 11.1% of patients with AF had 4 and more comorbidities. In patients with AF and with 4 and more comorbidities, the risk of death from all causes is almost seven times higher than in patients without comorbidities. As shown by the post hoc analysis of the ARISTOTLE study, apixaban was equally effective and safe in both patients without concomitant pathology and in muliborbid patients. The efficacy and safety of apixaban has been shown in AF and concomitant arterial hypertension, heart failure, coronary heart disease, including in patients with acute coronary syndrome, diabetes mellitus, chronic kidney disease and chronic obstructive pulmonary disease. The data of scientific research in recent years are reflected in the recommendations of the Ministry of Health of the Russian Federation on AF (2020), which presents a separate section on the management of patients with concomitant diseases. It is emphasized that apixaban has shown its superiority over warfarin and other direct oral anticoagulants in terms of efficacy and safety, both in isolated AF and in patients with concomitant diseases, which makes its choice preferable in the treatment of multimirbidity AF patients.

scholarly journals High prevalence of undiagnosed COPD among patients evaluated for suspected myocardial ischaemia

Open Heart ◽  
2018 ◽  
Vol 5 (2) ◽  
pp. e000848 ◽  
Author(s):  
Andreas Jönsson ◽  
Artur Fedorowski ◽  
Gunnar Engström ◽  
Per Wollmer ◽  
Viktor Hamrefors
Keyword(s):  
Myocardial Ischaemia ◽  
Chronic Obstructive Lung Disease ◽  
Chronic Obstructive ◽  
Clinical Factors ◽  
Obstructive Pulmonary Disease ◽  
Presenting Symptoms ◽  
High Prevalence ◽  
History Of ◽  
Artery Disease ◽  
Global Initiative

ObjectiveChronic obstructive pulmonary disease (COPD) and coronary artery disease (CAD) are leading causes of global morbidity and mortality. Despite the well-known comorbidity between COPD and CAD, the presence of COPD may be overlooked in patients undergoing coronary evaluation. We aimed to assess the prevalence of undiagnosed COPD among outpatients evaluated due to suspected myocardial ischemia.MethodsAmong 500 outpatients who were referred to myocardial perfusion imaging due to suspected stable myocardial ischaemia, 433 patients performed spirometry. Of these, a total of 400 subjects (age 66 years; 45% women) had no previous COPD diagnosis and were included in the current study. We compared the prevalence of previously undiagnosed COPD according to spirometry criteria from The Global Initiative for Chronic Obstructive Lung Disease (GOLD) or lower limit of normal (LLN) and reversible myocardial ischaemia according to symptoms and clinical factors.ResultsA total of 134 (GOLD criteria; 33.5 %) or 46 patients (LLN criteria; 11.5%) had previously undiagnosed COPD, whereas 55 patients (13.8 %) had reversible myocardial ischaemia. The presenting symptoms (chest discomfort, dyspnoea) did not differ between COPD, myocardial ischaemia and normal findings. Except for smoking, no clinical factors were consistently associated with previously undiagnosed COPD.ConclusionsAmong middle-aged outpatients evaluated due to suspected myocardial ischaemia, previously undiagnosed COPD is at least as common as reversible myocardial ischaemia and the presenting symptoms do not differentiate between these entities. Patients going through a coronary ischaemia evaluation should be additionally tested for COPD, especially if there is a positive history of smoking.

scholarly journals Thyroid Gland Disease as a Comorbid Condition in COPD

2021 ◽  
Vol 2021 ◽  
pp. 1-6
Author(s):  
Aziz Gumus ◽  
Neslihan Ozcelik ◽  
Bilge Yilmaz Kara ◽  
Songul Ozyurt ◽  
Unal Sahin
Keyword(s):  
Thyroid Gland ◽  
Multinodular Goiter ◽  
Airflow Limitation ◽  
Chronic Obstructive ◽  
Comorbid Condition ◽  
Thyroid Function Tests ◽  
Comorbid Conditions ◽  
Obstructive Pulmonary Disease ◽  
Euthyroid Sick Syndrome ◽  
Artery Disease

Introduction. Chronic obstructive pulmonary disease (COPD) is one of the most common causes of morbidity and mortality worldwide. The disease is characterized by progressive airway inflammation, which not only affects the airways but also has systemic effects that are associated with comorbidities. Although comorbid conditions such as hypertension and coronary artery disease are very well-known in COPD patients, diseases of the thyroid gland have not been sufficiently studied. Therefore, thyroid diseases are not considered among the comorbid conditions of COPD. The purpose of this study was to determine the thyroid gland disease (TGD) prevalence in COPD and associated factors. Materials and Method. The study included 309 (297 (96%) male) patients. The patients were subjected to spirometry and thyroid function tests (TFT) in the stable period. The thyroid gland disease they were diagnosed with was recorded after face-to-face meetings and examining their files. Results. The mean age of the patients who were included in the study was 65.9 ± 9.8 (40-90). Thyroid disease was determined in 68 (22%) individuals. There were hypothyroidism in 7 (2%), euthyroidism in 45 (15%), and hyperthyroidism in 16 (%5) patients. No relationship was found between the severity of airflow limitation and the prevalence of TGD. Conclusion. Thyroid abnormalities are commonly observed in COPD. The most frequently encountered TGDs are euthyroid multinodular goiter, euthyroid sick syndrome (ESS), and toxic multinodular goiter.

Abstract 15693: Comorbidities in Heart Failure: A Population-Based Case-control Study

Circulation ◽  
2015 ◽  
Vol 132 (suppl_3) ◽  
Author(s):  
Alanna M Chamberlain ◽  
Cynthia M Boyd ◽  
Sheila M Manemann ◽  
Shannon M Dunlay ◽  
Yariv Gerber ◽  
...  
Keyword(s):  
Heart Failure ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Chronic Conditions ◽  
Population Based ◽  
Chronic Obstructive ◽  
Diagnostic Code ◽  
Obstructive Pulmonary Disease ◽  
Comorbidity Burden ◽  
Artery Disease

Background: Whether age alone explains the comorbidity burden in heart failure (HF) is unclear. In particular, differences in the burden of co-morbid conditions in HF patients compared to population controls has not been well documented. Methods: The prevalence of 17 chronic conditions defined by the US Department of Health and Human Services were obtained in 1746 incident HF patients from 2000-2010 and controls matched 1:1 on sex and age from Olmsted County, MN. Conditions were ascertained requiring 2 occurrences of a diagnostic code. Logistic regression determined associations of each condition with HF. Results: Among the 1746 matched pairs (mean age 76.2 years, 43.5% men), the prevalence was higher in HF cases for all conditions (p<0.05) except dementia and osteoporosis. After adjusting for all conditions, hypertension, coronary artery disease, arrhythmia, asthma, chronic kidney disease, chronic obstructive pulmonary disease, diabetes, hepatitis, and substance abuse were significantly more common in HF (figure). More than a 2-fold increased odds of hepatitis, arrhythmia, and coronary artery disease was observed among HF cases. Arrhythmia (34.2%), hypertension (31.1%), and coronary artery disease (27.8%) had the largest attributable risk of HF; for example, assuming a causal relationship, if arrhythmias were eliminated, 34% of HF would be avoided. Conclusions: Compared to age- and sex-matched controls, HF patients have a higher prevalence of many chronic conditions, indicating the excess comorbidity in HF is not due to age alone. Some cardiovascular conditions, including arrhythmia, coronary artery disease, and hypertension were more common in HF. Of the non-cardiovascular conditions, hepatitis had the strongest association with HF and was an unanticipated finding that deserves additional investigation. It is important to understand comorbidities as they play a key role in the excess mortality and healthcare utilization experienced by HF patients.

Sign in / Sign up

Export Citation Format

Share Document